Skip to content
altrx

GLP-1 and Kidney Disease: The FLOW Trial That Stopped Early Because the Results Were That Clear

GLP-1 and Kidney Disease: The FLOW Trial That Stopped Early Because the Results Were That Clear

July 6, 2026
GLP-1 and Fatty Liver Disease: What the ESSENCE Trial Found

GLP-1 and Fatty Liver Disease: What the ESSENCE Trial Found

July 6, 2026
Semaglutide Cut Heart Attack Risk by 20% in People Without Diabetes. Here Is What the SELECT Trial Found.

Semaglutide Cut Heart Attack Risk by 20% in People Without Diabetes. Here Is What the SELECT Trial Found.

July 6, 2026
Retatrutide: The Weight Loss Drug That Outperformed Everything

Retatrutide: The Weight Loss Drug That Outperformed Everything

July 2, 2026
Strength Training vs. Cardio on GLP-1

Strength Training vs. Cardio on GLP-1

July 2, 2026
What Happens When You Stop Taking GLP-1?

What Happens When You Stop Taking GLP-1?

July 2, 2026
CGM for Everyone: Why Non-Diabetics Are Using Glucose Monitors to Optimize Health 

CGM for Everyone: Why Non-Diabetics Are Using Glucose Monitors to Optimize Health 

June 11, 2026
Metabolic Flexibility: The Metabolic Syndrome Reversal Your Doctor Isn’t Talking About 

Metabolic Flexibility: The Metabolic Syndrome Reversal Your Doctor Isn’t Talking About 

June 11, 2026

Trending Posts

Discover top trending posts from our blog.

GLP-1 and Kidney Disease: The FLOW Trial That Stopped Early Because the Results Were That Clear

GLP-1 and Kidney Disease: The FLOW Trial That Stopped Early Because the Results Were That Clear

July 6, 2026

Ray, a 62-year-old retired mail carrier from Memphis, had lived with type 2 diabetes for eleven years. He managed it reasonably well: A1c mostly in...

GLP-1 and Fatty Liver Disease: What the ESSENCE Trial Found

GLP-1 and Fatty Liver Disease: What the ESSENCE Trial Found

July 6, 2026

Latrice, a 48-year-old teacher from Atlanta, went in for a routine physical in early 2023....

Semaglutide Cut Heart Attack Risk by 20% in People Without Diabetes. Here Is What the SELECT Trial Found.

Semaglutide Cut Heart Attack Risk by 20% in People Without Diabetes. Here Is What the SELECT Trial Found.

July 6, 2026

Tony, a 59-year-old retiree from Phoenix, had his first heart attack at 55. His cardiologist...

Retatrutide: The Weight Loss Drug That Outperformed Everything

Retatrutide: The Weight Loss Drug That Outperformed Everything

July 2, 2026

What the Data Shows and When It Arrives When Ozempic delivered 15% body weight loss,...

  • Uncategorized

    GLP-1 and Kidney Disease: The FLOW Trial That Stopped Early Because the Results Were That Clear

    July 6, 2026

    Ray, a 62-year-old retired mail carrier from Memphis, had lived with type 2 diabetes for eleven years. He managed it reasonably well: A1c mostly in the low sevens, blood pressure controlled, no amputations, no serious eye complications. He credited his nephrologist, Dr. Simmons, with keeping him honest. What Dr. Simmons tracked closely…

    Continue Reading
  • Uncategorized

    GLP-1 and Fatty Liver Disease: What the ESSENCE Trial Found

    July 6, 2026

    Latrice, a 48-year-old teacher from Atlanta, went in for a routine physical in early 2023. She felt fine. Her main concern was her weight, which had climbed to 218 pounds since her late thirties. Her doctor ordered a metabolic panel. Her liver enzymes came back elevated. An ultrasound confirmed fatty…

    Continue Reading
  • Uncategorized

    Semaglutide Cut Heart Attack Risk by 20% in People Without Diabetes. Here Is What the SELECT Trial Found.

    July 6, 2026

    Tony, a 59-year-old retiree from Phoenix, had his first heart attack at 55. His cardiologist put him on a statin, aspirin, and a beta-blocker. He lost 12 pounds through diet changes. Then life got busy, and the weight came back. By 2023 he was carrying 247 pounds on a 5’10″…

    Continue Reading
  • Uncategorized

    Retatrutide: The Weight Loss Drug That Outperformed Everything

    July 2, 2026

    What the Data Shows and When It Arrives When Ozempic delivered 15% body weight loss, people called it a revolution. When Mounjaro arrived with 21%, it was described as a step change. Then the Phase 2 data for retatrutide landed in the New England Journal of Medicine, and researchers went…

    Continue Reading
  • Uncategorized

    Strength Training vs. Cardio on GLP-1

    July 2, 2026

    What Actually Maximizes Fat Loss and Protects Your Muscle When Ryan, a 44-year-old from Phoenix, started tirzepatide, his doctor told him to “exercise more.” So he did what most people do: he started running. Three miles every morning. By month four, he’d lost 31 pounds and felt weaker than he…

    Continue Reading
  • Uncategorized

    What Happens When You Stop Taking GLP-1?

    July 2, 2026

    The Truth About Weight Regain and What to Do Instead A woman in Nashville started Ozempic in January 2024. By August, she’d lost 38 pounds. By December, she stopped. Her insurance dropped coverage and the cash price was $936 a month. By the following summer, she’d regained 27 of those…

    Continue Reading
  • Glucose-Monitors
    Uncategorized

    CGM for Everyone: Why Non-Diabetics Are Using Glucose Monitors to Optimize Health 

    June 11, 2026

    For decades, continuous glucose monitors (CGMs) were only for people with diabetes. But in 2026, this is changing. Healthy people without diabetes are using CGMs to understand how their body responds to food, stress, sleep, and exercise.  The reason is simple: your blood sugar patterns reveal how well your metabolic…

    Continue Reading
  • Uncategorized

    Metabolic Flexibility: The Metabolic Syndrome Reversal Your Doctor Isn’t Talking About 

    June 11, 2026

    Your body is supposed to be a metabolic shapeshifter. Fed all day on carbohydrates, you burn carbohydrates. Food-deprived for 14 hours, you burn fat. Intense exercise coming, you mobilize glucose. Walking after dinner, you burn stored energy.  This ability is called metabolic flexibility. And if you have metabolic syndrome, you’ve lost it entirely.  Most people don’t know they lack metabolic flexibility…

    Continue Reading
  • Uncategorized

    Sleep Optimization and Circadian Rhythm Hacking: The Overlooked Foundation of Longevity 

    June 11, 2026

    Your body runs on a 24-hour clock. Not metaphorically. Your cells have a master circadian rhythm that controls when you sleep, when your cortisol rises, when your metabolism peaks, and how well your brain clears toxic proteins at night.  Most people ignore this clock entirely. They sleep whenever they get…

    Continue Reading
  • Uncategorized

    Scientists Just Reversed Alzheimer’s in Mice Using Nanotechnology: Here’s What It Means 

    June 11, 2026

    In May 2026, researchers published findings that made headlines in neuroscience circles and rippled across medical and longevity communities: engineered nanoparticles reversed Alzheimer’s disease pathology in mice, restoring memory and cognitive function in a matter of hours. Read the full research: https://www.nature.com/articles/s41467-026-xxxxx  This represents something crucial: a fundamental shift in how scientists…

    Continue Reading
 Older Posts

Recent Posts

  • GLP-1 and Kidney Disease: The FLOW Trial That Stopped Early Because the Results Were That Clear
  • GLP-1 and Fatty Liver Disease: What the ESSENCE Trial Found
  • Semaglutide Cut Heart Attack Risk by 20% in People Without Diabetes. Here Is What the SELECT Trial Found.
  • Retatrutide: The Weight Loss Drug That Outperformed Everything
  • Strength Training vs. Cardio on GLP-1

Reviews

  • Newswire - AltRx GLP-1 Review
  • GetWellFamily GLP-1 Reviews
  • Dalton Family - AltRx GLP-1 Reviews
  • Dean Silver MD - AltRx GLP-1
  • Clark Family Med GLP-1 Reviews
  • MedicalNews - AltRx GLP-1 Results
  • Scribe - AltRx GLP-1 Weight Management
  • AltRx GLP-1 – Worth It?
  • CompareWeightMeds - AltRx Review
  • Neha Net - AltRx GLP-1 & Weight Loss
Graceful Theme by Optima Themes
English
Spanish